title: Osteolymphoma (primary bone lymphoma): an Australian review of 70 cases. Australasian Radiation Oncology Lymphoma Group (AROLG).
abstract: BACKGROUND
  To examine prognostic factors, treatment outcomes and design future studies for Osteolymphoma (OL)--also known as primary bone lymphoma.
  
  
  METHODS
  Between 1979 and 1993, 70 patients with OL were treated in nine Australian centres. The effect of patient-, tumour-, and treatment-related factors on local control, distant disease-free survival and overall survival were assessed by multivariate analysis.
  
  
  RESULTS
  Most patients (94%) received radiotherapy (RT) (median dose 40 Gy) and 56% received chemotherapy. Multifocal disease was present in 20% of patients. The five year rates of overall survival and local control were 59% and 82%. Although there was a trend towards better results with the addition of chemotherapy, on multivariate analysis, there were no factors identified which appeared to impact upon overall and disease-free survival. Among the distant recurrences, there was a high proportion in bone (33%). Six patients suffered pathological fractures after treatment.
  
  
  CONCLUSIONS
  High rates of local control were achieved by RT, but the overall survival remains relatively poor, worse than nodal lymphoma. The natural history of the disease suggests that OL may be a distinct entity, different to nodal lymphomas, so the results of clinical trials in nodal lymphoma may not be relevant to OL. Prospective studies could define the outcome of combined modality therapy and set a benchmark for testing further proposals, as well as improving our knowledge of the clinical features of OL.
authors.affiliation: East Coast Cancer Centre, John Flynn Hospital, Tugun, Qld.
authors.forename: D R
authors.initials: DR
authors.lastname: Christie
authors.forename: M B
authors.initials: MB
authors.lastname: Barton
authors.forename: G
authors.initials: G
authors.lastname: Bryant
authors.forename: R
authors.initials: R
authors.lastname: Cheuk
authors.forename: V
authors.initials: V
authors.lastname: Gebski
authors.forename: J
authors.initials: J
authors.lastname: Hornsey
authors.forename: D
authors.initials: D
authors.lastname: Lonergan
authors.forename: C
authors.initials: C
authors.lastname: MacLeod
authors.forename: G
authors.initials: G
authors.lastname: Pratt
authors.forename: D
authors.initials: D
authors.lastname: Roos
authors.forename: J
authors.initials: J
authors.lastname: Shannon
authors.forename: D
authors.initials: D
authors.lastname: Thornton
authors.forename: A
authors.initials: A
authors.lastname: Wirth
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents